DekaBank Deutsche Girozentrale - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 483 filers reported holding CRISPR THERAPEUTICS AG in Q1 2024. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.

Quarter-by-quarter ownership
DekaBank Deutsche Girozentrale ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q2 2024$2,264
-19.3%
40,7450.0%0.00%
-20.0%
Q1 2024$2,807
+9.1%
40,745
+1.9%
0.01%0.0%
Q4 2023$2,572
+40.5%
40,0000.0%0.01%
+25.0%
Q3 2023$1,830
-19.8%
40,0000.0%0.00%
-20.0%
Q2 2023$2,281
+158.3%
40,000
+100.0%
0.01%
+150.0%
Q1 2023$883
+5.0%
20,000
-4.0%
0.00%0.0%
Q4 2022$841
-99.9%
20,843
+4.2%
0.00%
-50.0%
Q3 2022$1,304,000
-54.7%
20,000
-56.2%
0.00%
-50.0%
Q2 2022$2,877,000
-1.7%
45,6600.0%0.01%
+14.3%
Q1 2022$2,926,000
+8.4%
45,660
+29.9%
0.01%0.0%
Q4 2021$2,699,000
-51.8%
35,160
-30.8%
0.01%
-56.2%
Q3 2021$5,599,000
-17.0%
50,810
+13.4%
0.02%
-20.0%
Q2 2021$6,744,000
+61.2%
44,810
+23.4%
0.02%
+42.9%
Q1 2021$4,183,000
+62.5%
36,310
+122.6%
0.01%
+40.0%
Q4 2020$2,574,000
+125.2%
16,310
+21.3%
0.01%
+100.0%
Q3 2020$1,143,00013,4500.01%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q1 2024
NameSharesValueWeighting ↓
Versant Venture Management, LLC 508,558$82,330,00027.28%
Valiant Capital Management, L.P. 307,700$49,814,0003.74%
NEA Management Company, LLC 1,590,002$257,405,0003.35%
NIA IMPACT ADVISORS, LLC 39,891$6,458,0003.15%
Ikarian Capital, LLC 200,000$32,379,0002.62%
Soleus Capital Management, L.P. 103,114$16,693,0002.57%
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. 157,334$25,471,0002.47%
Capital Impact Advisors, LLC 45,440$7,356,0002.37%
ARK Investment Management 7,776,119$1,258,876,0002.34%
Sassicaia Capital Advisers LLC 13,513$2,188,0002.28%
View complete list of CRISPR THERAPEUTICS AG shareholders